Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Hospira Japan Launches Its 1st In-house Oncology Generics
December 13, 2010
- Astellas Obtains Oncology Technology Platform from AVEO
December 13, 2010
- Itochu, PRISM BioLab to Market Library of Chemical Compounds
December 13, 2010
- Generics Should Be Priced at Lower Levels in Japan: Dr Eiki of Bayer Yakuhin
December 13, 2010
- Sawai to Re-Propose Merger to Kyorin
December 13, 2010
- Bayer, Regeneron to Apply for VEGF Trap-Eye in Europe, US in 2011
December 13, 2010
- Eisai to Donate Antifilarial Drug through WHO
December 13, 2010
- Global Players Accelerate Personnel Downsizing
December 13, 2010
- Takeda to Apply for Hematide in US in 2Q 2011
December 13, 2010
- “Vaccine Gap” in Japan Needs Immediate Resolution: Prof. Plotkin
December 13, 2010
- Develop More Drugs for Cancer, Hereditary Diseases: Mr Inoue
December 13, 2010
- Pharma Eight Starts New Drug Seeds Discovery in Okinawa
December 13, 2010
- Sanofi-aventis Completes Collection of PMS Case Report Forms for Lantus
December 13, 2010
- Major Drugstore Chain Operators Start Offering Points for Copayments for Dispensing Services
December 13, 2010
- OncoTherapy, Immunovaccine Enter Cancer Vaccine Research Agreement
December 13, 2010
- 79 Investigational Drugs for Alzheimer's Disease in Clinical Stage: PhRMA Report
December 13, 2010
- Astellas to Transfer Marketing of Protopic to Maruho
December 13, 2010
- Axitinib Extends PFS in mRCC Patients: Pfizer
December 13, 2010
- Ketotifen to Be Reclassified as Class 2 OTC Drug
December 13, 2010
- Takeda Licenses Baxter's Vero-Cell Based Flu Vaccine Technology
December 13, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…